Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 47-59 , January 2002

18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation

  • Hongming Zhuang
    • ,
  • Abass Alavi

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Abass Alavi, MD, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 110 Donner Bidg, 3400 Spruce St, Philadelphia, PA 19104.

References 

  1. Fischman A, Babich J, Strauss H. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med. 1993;4:2253–2263
  2. Boerman O, Oyen W, Corstens F, et al. Liposomes for scintigraphic imaging: optimization of in vivo behavior. Q J Nucl Med. 1998;42:271–279
  3. Samuel A, Paganelli G, Chiesa R, et al. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med. 1996;37:55–61
  4. Rusckowski M, Paganelli G, Hnatowich DJ, et al. Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. J Nucl Med. 1996;37:1655–1662
  5. Becker W, Goldenberg DM, Wolf F. The use of monoclonal-antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med. 1994;24:142–153
  6. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA. 2000;97:9226–9233
  7. Heelan BT, Osman S, Blyth A, et al. Use of 2-[F-18]fluoro-2-deoxyglucose as a potential agent in the prediction of graft rejection by positron emission tomography. Transplantation. 1998;66:1101–1103
  8. Lehmann K, Behe M, Meller J, et al. F-18-FDG uptake in granulocytes: Basis of F-18-FDG scintigraphy for imaging infection. J Nucl Med. 2001;42:1384
  9. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo—High accumulation in macrophages and granulation tissues studied by microautoradiograph. J Nucl Med. 1992;33:1972–1980
  10. (abstr) Mamede M, Saga T, Ishimori T, et al. Differential uptake of F-18-FDG in experimental tumors xenografted, into immunocompetent and immunodeficient mice and the effect of steroid pretreatment on tumor uptake. J Nucl Med. 2001;42:1172
  11. Chakrabrti R, Jung CY, Lee TP, et al. Changes in glucose-transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol. 1994;152:2660–2668
  12. Gamelli RL, Liu H, He LK, et al. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol. 1996;59:639–647
  13. Sorbara LR, Maldarelli F, Chamoun G, et al. Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. J Virol. 1996;70:7275–7279
  14. Ahmed N, Kansara M, Berridge MV. Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 affinity for glucose is enhanced during the respiratory burst. Biochem J. 1997;327:369–375
  15. Tahara T, Ichiya Y, Kuwabara Y, et al. High [18]-fluorodeoxyglucose uptake in abdominal absecesses: A PET study. J Comput Assist Tomogr. 1989;5:829–831
  16. Meyer MA, Frey KA, Schwaiger M. Discordance between F-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med. 1993;18:682–684
  17. Yen RF, Chen ML, Liu FY, et al. False-positive 2-[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formos Med Assoc. 1998;97:642–645
  18. Kaya Z, Kotzerke J, Keller F. FDG PET diagnosis of septic kidney in a renal transplant patient. Transpl Int. 1999;12:156
  19. Schroder W, Zimny M, Rudlowski C, et al. The role of F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer. 1999;9:117–122
  20. Zimny M, Schroder W, Wolters S, et al. 18F-fluorodeoxyglucose PET in ovarian carcinoma: Methodology and preliminary results. Nuklear medizin. 1997;36:228–233
  21. Jones HA, Sriskandan S, Peters AM, et al. Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Resp J. 1997;10:795–803
  22. Kapucu LO, Meltzer CC, Townsend DW, et al. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med. 1998;39:1267–1269
  23. Sugawara Y, Braun D, Kison P, et al. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results. Eur J Nucl Med. 1998;25:1238–1243
  24. Guhlmann A, Brecht-Krauss D, Suger G, et al. Chronic osteomyelitis: Detection with FDG PET and correlation with histopathologic findings. Radiology. 1998;206:749–754
  25. Guhlmann A, Brecht-Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy, in chronic osteomyelitis. J Nucl Med. 1998;39:2145–2152
  26. Zhuang HM, Duarte PS, Pourdehand M, et al. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med. 2000;25:281–284
  27. Zhuang HM, Duarte PS, Pourdehnad M, et al. The promising role of F-18-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med. 2001;42:44–48
  28. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487–490
  29. Bakheet SMB, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med. 1998;23:739
  30. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology. 2000;216:117–121
  31. Zhuang HM, Pourdehnad M, Yamamoto AJ, et al. Intense F-18 fluorodeoxyglucose uptake caused by Mycobacterium avium intracellulare infection. Clin Nucl Med. 2001;26:458
  32. Bakheet SMB, Powe J, Kandil A, et al. F-18-FDG uptake in breast infection and inflammation. Clin Nucl Med. 2000;25:100–103
  33. Hannah A, Scott AM, Akhurst T, et al. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. J Nucl Med. 1996;37:1683–1685
  34. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med. 1995;20:434–435
  35. Tomas MB, Tronco GG, Karayalcin G, et al. FDG uptake in infectious mononucleosis. Clin Position Imag. 2000;3:176
  36. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259–264
  37. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose, in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  38. Brudin LH, Valind SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305
  39. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positronemission tomography scanning: Potential for error in interpretation. Semin Nucl Med. 1996;26:308–314
  40. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160–1166
  41. Taylor IK, Hill AA, Hayes M, et al. Imaging allergen-invoked airway inflammation in atopic asthma with [18F]-fluorodeoxyglucose and positron emission tomography. Lancet. 1996;347:937–940
  42. Yasuda S, Shohtu A, Ide M, et al. Elevated F-18 FDG uptake in plasmacyte-rich chronic maxillary sinusitis. Clin Nucl Med. 1998;23:176–178
  43. Gysen M, Stroobants S, Mortelmans L. Proliferative myositis: A case of a pseudomalignant process. Clin Nucl Med. 1998;23:836–838
  44. Yasuda S, Shohtsu A, Ide M, et al. Diffuse F-18 FDG uptake in chronic thyroiditis. Clin Nucl Med. 1997;22:341
  45. Imran MB, Kubota K, Yoshioka S, et al. Sclerosing mediastinitis: Findings on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med. 1999;24:305–308
  46. Chang KJ, Zhuang HM, Alavi A. Detection of chronic recurrent lower extremity deep venous thrombosis on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med. 2000;25:838–839
  47. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med. 1999;24:281–282
  48. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Radiat Appl Instr Part B Nucl Med Biol. 1992;19:183–190
  49. Forstrom LA, Mullan BP, Hung JC, et al. F-18-FDG labelling of human leukocytes. Nucl Med Comm. 2000;21:691–694
  50. Sugawara Y, Gutowski TD, Fisher SJ, et al. Uptake of positron emission tomography tracers in experiental bacterial infections: A comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, Ga-67-citrate, and I-125-HSA. Eur J Nucl Med. 1999;26:333–341
  51. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185–191
  52. Kolindou A, Liu Y, Ozker K, et al. In-111 WBC imaging of osteomyelitis in patients with underlying bone scan abnormalities. Clin Nucl Med. 1996;21:183–191
  53. Merkel KD, Brown ML, Dewanjee MK, et al. Comparison of indium-labeled-leukocyte imaging with sequential technetium-gallium scanning in the diagnosis of low-grade musculoskeletal sepsis. J Bone Joint Surg Am. 1985;67:465–471
  54. Reske SN, Karstens JH, Gloeckner W, et al. Radioimmunoimaging for diagnosis of bone-marrow involvement in breast cancer and malignant lymphoma. Lancet. 1989;1:299–301
  55. Chung JK, Yeo J, Lee DS, et al. Bone marrow scintigraphy using technetium-99m-antigranulocyte antibody in hematologic disorders. J Nucl Med. 1996;37:978–982
  56. Jacobson AF, Gilles CP, Cerqueira MD. Photopenic defects in marrow-containing skeleton on in-111 leukocyte scintigraphy-Prevalence at sites suspected of osteomyelitis and as an incidental finding. Eur J Nucl Med. 1992;19:858–864
  57. Gratz S, Braun HG, Behr TM, et al. Photopenia in chronic vertebral osteomyelitis with technetium- 99m-antigranulocyte antibody (BW 250/183). J Nucl Med. 1997;38:211–216
  58. Robiller FC, Stumpe KDM, Kossmann T, et al. Chronic osteomyelitis of the femur: Value of PET imaging. Eur Radiol. 2000;10:855–858
  59. (abstr) De Winter F, Van de Wiele C, Vogelaers D, et al. FDG PET is highly accurate in the diagnosis of chronic osteomyelitis in the central skeleton. J Nucl Med. 2000;41:57
  60. (abstr) De Winter F, Dierckx R, De Bondt P, et al. FDG PET as a single technique is more accurate than the combination bone scan/white blood cell scan in chronic orthopedic infections (COI). J Nucl Med. 2000;41:59
  61. Schmitz A, Kalicke T, Willkomm P, et al. Use of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in assessing the process of tuberculous spondylitis. J Spinal Disord. 2000;13:541–544
  62. Fitzgerald RH. Diagnosis and management of the infected hiprosthesis. Orthopedics. 1995;18:833–835
  63. Bauer GCH, Lindberg L, Naverstein Y, et al. Radionuclide scintimetry in infected total hip arthroplasty. Acta Orthop Scand. 1973;44:439–450
  64. Kraemer WJ, Saplys R, Waddell JP, et al. Bone scan, gallium scan, and hip aspiration in the diagnosis of infected total hip arthroplasty. J Arthroplasty. 1993;8:611–616
  65. Mulamba LAH, Ferrant A, Lencers N, et al. Indium-111-leukocyte scanning in the evaluation of painful hip arthroplasty. Acta Orthop Scand. 1983;54:695–697
  66. Palestro CJ, Kim CK, Swyer AJ, et al. Total-hip arthroplasty: Periprosthetic indium-111 labeled leukocyte activity and complementary technetium-99m-sulfur colloid imaging in suspected infection. J Nucl Med. 1990;31:1950–1954
  67. Palestro CJ, Roumanas P, Swyer AJ, et al. Diagnosis of musculosk-eletal infection using combined In-111 labeled leukocyte and Tc-99m SC marrow imaging. Clin Nucl Med. 1992;17:269–273
  68. Scher DM, Pak K, Lonner JH, et al. The predictive value of indium-111 leukocyte scans in the diagnosis of infected total hip, knee, or resection arthroplasties. J Arthroplastry. 2000;15:295–300
  69. (abstr) De Winter F, Van de Wiele C, Verdonk R, et al. FDF PET for the exclusion of infection in orthopedic prostheses. J Nucl Med. 2000;41:1421
  70. Heiba SI, Luo JQ, Sadek S, et al. Attenuation correction induced artifiact in F-18 FDG PET imaging following total knee replacement. Clin Positron Imag. 2000;3:237–239
  71. Kalicke T, Schmitz A, Risse JH, et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: Results of histologically confirmed cases. Eur J Nucl Med. 2000;27:524–528
  72. Schmitz A, Risse HJ, Kalicke T, et al. FDG-PET for diagnosis and follow-up of inflammatory processes: First results from an orthopedic view. Z Orthop Grenzg. 2000;138:407–412
  73. Stumpe KDM, Dazzi H, Schaffner A, et al. Infection imaging using whole-body FDG-PET. Eur J Nucl Med. 2000;27:822–832
  74. (abstr) Manthey P, Reinhard P, Tatsch K, et al. FDG PET to differentiate between loosening and infection of hip and knee prostheses. J Nucl Med. 1999;40:96
  75. (abstr) Love C, Sarkar SD, Durojaye AO, et al. Diagnosing the infected joint replacement: A prospective comparison of F-18FDG, bone gallium, and leukocyte/marrow scintigraphy. Radiology. 2000;217:499
  76. (abstr) Love C, Marwin SE, Krauss ES, et al. Diagnosing the infected joint replacement: Prospective intraindividual comparison of In-111 labeled leukocyte/marrow and F-18 FDG imaging. J Nucl Med. 2000;41:58P
  77. Zhuang HM, Moussavian B, Ponzo F, et al. The location, not intensity, of the tracer uptake, is a critical criterion in making a correct diagnosis of periprosthetic infection in patients with painful hip prostheses by FDG-PET. J Nucl Med. 2001;42:482
  78. De Winter F, Van de Wiele C, De Clercq D, et al. Aseptic loosening of a knee prosthesis as imaged on FDG positron emission tomography. Clin Nucl Med. 2000;25:923
  79. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for. J Nucl Med. 1998;39:1302–1305
  80. Zhuang HM, Moussavian B, Liu FM, et al. Persistent non-specific tracer uptake on FDG-PET following hip arthroplasty and its evaluation over time. J Nucl Med. 2001;42:477
  81. Peters AM. The use of nuclear medicine in infections. Br J Radiol. 1998;71:252–261
  82. Scharko AM, Perlman SB, Hinds PW, et al. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci USA. 1996;93:6425–6430
  83. Wallace M, Pyzalski R, Horejsh D, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology. 2000;274:255–261
  84. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–1582
  85. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567–575
  86. Heald AE, Hoffman JM, Bartlett JA, et al. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7:337
  87. Villringer K, Jager H, Dichgans M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr. 1995;19:532–536
  88. Muller-Quernheim J. Sarcoidosis: Clinical manifestations, staging and therapy (part II). Respirat Med. 1998;92:140–149
  89. Yasuda S, Shohtsu A, Ide M, et al. High fluorine-18 labeled deoxyglucose uptake in sarcoidosis. Clin Nucl Med. 1996;21:983–984
  90. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer. 1996;73:882–886
  91. Gotway MB, Storto ML, Golden JA, et al. Incidental detection of thoracic sarcoidosis on whole-body (18)fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography. J Thorac Imag. 2000;15:201–204
  92. Kiatboonsri C, Resnick SC, Chan KM, et al. The detection of recurrent sarcoidosis by FDG-PET in a lung transplant recipient. West J Med. 1998;168:130–132
  93. Joe A, Hoegerle S, Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18FDG positroa emission tomography. Clin Nucl Med. 2001;26:542
  94. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med. 1994;35:1650–1652
  95. Peters AM. Nuclear medicine imaging in fever of unknown origin. Q J Nucl Med. 1999;43:61
  96. Turlakow A, Yeung HWD, Pui J, et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med. 2001;161:1003–1007
  97. De Winter F, Petrovic M, Van de Wiele C, et al. Imaging of giant cell arteritis—Evidence of splenic involvement using FDG positron emission tomography. Clin Nucl Med. 2000;25:633–634
  98. (abstr) Maes A, Blockmans D, Stroobants S, et al. Diagnosis of systemic vasculitis using positron emission tomography. J Nucl Med. 1998;39:1170
  99. Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr. 1999;23:16–18
  100. Blockmans D, Maes A, Stroobants S, et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology. 1999;38:444–447
  101. Derdelinckx I, Maes A, Bogaert J, et al. Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiologica. 2000;55:193–195
  102. (abstr) Engel-Bicik I, Seger R, Eich G, et al. Diagnostic and therapeutic impact of whole body PET with FDG in immunodeficient children and fever of unknown origin. Eur J Nucl Med. 1999;26:OS58
  103. Stein PD, Afzal A, Henry JW, et al. Fever in acute pulmonary embolism. Chest. 2000;117:39–42
  104. Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest. 1997;111:661–664
  105. Lin EC, Quaife RA. FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging. Clin Nucl Med. 2001;26:241–242
  106. Dreyer M, Borgwardt L, Reichnitzer C, et al. The role of whole body FDG-PET in pediatric patients with fever of unknown origin. J Nucl Med. 2001;42:142
  107. Meller J, Altenvoerde G, Munzel U, et al. Fever of unknown origin: Prospective comparison of [F-18]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med. 2000;27:1617–1625
  108. (abstr) Meller JJ, Sahlmann C, Lehmann K, et al. Postoperative fever: Prospective evaluation of 18 FDG-imaging with a double head coincidence camera (DHCC). J Nucl Med. 2001;42:1377
  109. (abstr) Mortelmans LA, De Caestecker J, Maes A, et al. Diagnostic role of whole body FDG PET in patients with fever of unknown origin (FUO). J Nucl Med. 1999;40:201P
  110. Blockmans D, Knockaert D, Maes A, et al. Clinical value of [F-18]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis. 2001;32:191–196
  111. Theron J, Tyler JL. Takayasus-arteritis of the aortic-arch—Endovascular treatment and correlation with positron emission tomography. Am J Neuroradiol. 1987;8:621–626
  112. Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood. 1998;92:2719
  113. Franzius C, Biermann M, Hulskamp G, et al. Therapy monitoring in aspergillosis using F-18FDG positron emission tomography. Clin Nucl Med. 2001;26:232–233
  114. Reuter S, Schirrmeister H, Kratzer W, et al. Pericystic metabolic activity in alveolar echinococcosis: Assessment and follow-up by positron emission tomography. Clin Infect Dis. 1999;29:1157–1163
  115. Eisenberg S, Aksentijevich I, Deng ZM, et al. Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med. 1998;129:539
  116. Laleman W, Vanderschueren S, Mortelmans L, et al. Progressive bouts of acute abdomen: Pet the peritoneum. Acta Clinica Belgica. 2001;56:46–50
  117. (abstr) Jacobson K, Mernagh JR, Nahmias C, et al. FDG-PET: An investigative tool in pediatric inflammatory bowel disease. Gastroenterology. 1997;112:A880
  118. (abstr) Vehling D, Neurath M, Siessmeier T, et al. FDG-PET, antigranulocyte-scintigraphy and hydro-MRI in the determination of bowel wall inflammation in Crohns disease. J Nucl Med. 2000;41:11P
  119. (abstr) Jacobson K, Mernagh JR, Green T, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Gastroenterology. 1999;116:A742
  120. Neurath MF, Vehling M, Schunk K, et al. FDG-PET: A novel non-invasive method to detect affected bowel segments in Crohn's disease?. Gastroenterology. 2000;118:1749
  121. Bicik I, Bauerfeind P, Breitbach T, et al. Inflammatory bowel disease activity measured by positron-emission tomography. Lancet. 1997;350:262
  122. Charron M, del Rosario JF, Kocoshis S. Use of technetiumtagged white blood cells in patients with Crohn's disease and ulcerative colitis: Is differential diagnosis possible?. Pediatr, Radiol. 1998;28:871–877
  123. Charron M, Del Rosario F, Kocoshis S. Assessment of terminal ileal and colonic inflammation in Crohn's disease with 99mTc-WBC. Acta Paediatr. 1999;88:193–198
  124. Stahl A, Weber WA, Avril N, et al. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin. 2000;39:241–245
  125. (abstr) Stumpe KD, Kossmann T, Von Schulthess GK. FDG-PET imaging of infections of vascular and metallic implants. Radiology. 1999;213P:657
  126. Salem SS, Heiba S, Santiago J, et al. Unusual presentation of solitary bone metastasis from breast carcinoma mimicking acute osteomyelitis of the left midtibial shaft. Clin Nucl Med. 2000;25:480–481
  127. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesion using “quantitative” parameters of FDG PET images. Clin Nucl Med. 1996;21:941–949
  128. Torizuka T, Zasadny KR, Recker B, et al. Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology. 1998;207:767–774
  129. (abstr) Zhuang HM, Lee JH, Pourdehnad M, et al. In vitro investigation of FDG uptake in human inflammatory cells. J Nucl Med. 1999;40:198P
  130. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306
  131. (abstr) Nakamoto Y, Higashi T, Sakahara H, et al. Delayed FDG-PET scan for the differentiation between malignant and benign lesions. J Nucl Med. 1999;40:247P
  132. (abstr) Kubota K, Yamaguchi K, Itoh M, et al. Whole body FDG-PET for tumor detection should be imaged at 2 hr after injection. J Nucl Med. 1999;40:141P
  133. (abstr) Herzog HR, Borner AR, Weckesser M, et al. Delayed scan time for FDG-PET in breast cancer. J Nucl Med. 1999;40:140P
  134. (abstr) Ishizu K, Nakamura S, Shiozaki T, et al. Inceasing rate of FDG uptake from early to delayed PET images in lung tumors. J Nucl Med. 2000;41:76P
  135. Wahl RL, Henry CA, Ethier SP. Serum glucose—Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary-carcinoma. Radiology. 1992;183:643–647
  136. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355–359
  137. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer—A PET study. J Nucl Med. 1993;34:1–6
  138. Diederichs CG, Staib L, Glatting G, et al. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030–1033
  139. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumors and inflammatory lesions. Eur J Nucl Med. 2001;28:730–735
  140. (abstr) Zhuang HM, Loman JC, Cortes-Blanco A, et al. Hyperglycemia does not adversely affect FDG uptake by inflammatory and infectious lesions in FDG-PET imaging. J Nucl Med. 2000;41:1396
  141. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock. 2000;13:379–385
  142. Weisdorf DJ, Craddock PR, Jacob HS. Gramulocytes utilize different energy sources for movement and phagocytosis. Inflammation. 1982;6:245–256
  143. Lang CH, Bagby GJ, Dobrescu C, et al. Modulation of glucose metabolic response to endotoxin by granulocyte colony-stimulating factor. Am J Physiol. 1992;263:R1122–R1129
  144. Chang HR, Bistrian B. The role of cytokines in the catabolic consequences of infection and injury. J Parenter Enter Nutr. 1998;22:156–166
  145. Yao WJ, Hoh CK, hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794–799
  146. (suppl) Tetta C, Mariano F, Buades J, et al. Relevance of platelet-activating factor in inflammation and sepsis: Mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis. 1997;30:S57–S65
  147. deKleijn E, Telgt D, Laan R. Schnitzler's syndrome presenting as fever of unknown origin (FUO—The role of cytokines in its systemic features. Neth J Med. 1997;51:140–142
  148. Martin T, Losa JE, Garciasalgado MJ, et al. The role of platelet-activating-factor (Paf) in interstitial pulmonary disease. J Investig Allergol Clin Immunol. 1994;4:149–157
  149. Yue TL, Rabinovici R, Feuerstein G. Platelet-activating factor (PAF)—A putative mediator in inflammatory tissue injury. Ad Exp Med Biol. 1991;314:223–233
  150. Lang CH, Dobrescu C, Hargrove DM, et al. Platelet-activating factor-induced increases in glucose kinetics. Am J Physiol. 1988;254:E193–E200
  151. Ottlakan A. Role of platelet-activating factor in glucose uptake and utilization of different tissues. Eur Surg Res. 1998;30:393–402
  152. Shearer JD, Amaral JF, Caldwell MD. Glucose metabolism of injured skeletal muscle: The contribution of inflammatory cells. Circ Shock. 1988;25:131–138
  153. Goswami GK, Jana S, Santiago JF, et al. Discrepancy between Ga-67 citrate and F-18 fluorodeoxyglucose positron emission tomographic scans in pulmonary infection. Clin Nucl Med. 2000;25:490–491
  154. Temmerman OPP, Heyligers IC, Hoekstra OS, et al. Detection of osteomyelitis using (18)FDG and positron emission tomography. J Arthroplasty. 2001;16:243–246
  155. Chisholm PM, Danpure HJ, Healey G, et al. Cell damage resulting from the labeling of rat lymphocytes and Hela S3 cells with In-111 oxine. J Nucl Med. 1979;20:1308–1311
  156. Kuyama J, McCormack A, George AJ, et al. Indium-111 labelled lymphocytes: Isotope distribution and cell division. Eur J Nucl Med. 1997;24:488–496
  157. Kobayashi A, Shinozaki T, Shinjyo Y, et al. FDG PET in the clinical evaluation of sarcoidosis with bone lesions. Ann Nucl Med. 2000;14:311–313
  158. (abstr) Fischman AJ, Carter EA, Coco-Graham WA, et al. Comparison, of a Tc-99m chemotactic peptide with (18)FDG for imaging infection, and sterile inflammation in rabbits. J Nucl med. 1999;40:894
  159. de Vries EFJ, van Waarde A, Harmsen MC, et al. [C-11]FMAU and [F-18]FHPG as, PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nucl Med Biol. 2000;27:113–119
  160. Takasu A, Shimosegawa T, Shimosegawa E, et al. [C-11] methionine positron emission tomography for the, evaluation of pancreatic exocrine function in chronic pancreatitis. Pancreas. 2001;22:203–209
  161. (abstr) Oriuchi N, Inoue T, Tomiyoshi K, et al. F-18-fluoro-alpha-methyltyrosine (FMT) and F-18-fluorodeoxyglucose (FDG) PET in patients with sarcoidosis. J Nucl Med. 1999;40:196P
  162. Liu RS, Chu LS, Yen SH, et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med. 1996;23:1384–1387
  163. Slavin RG, Leipzig JR, Goodgold HM. “Allergic sinusitis” revisited. Ann Allergy Asthma Immunol. 2000;85:275–278
  164. (abstr) Brownell A-L, Chen Y-I, Cicchetti F, et al. Is inflammation a factor in neurodegeneration. J Nucl Med. 2000;41:407

PII: S0001-2998(02)80039-3

doi: 10.1053/snuc.2002.29278

Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 47-59 , January 2002

Article Tools